Humana (NYSE: HUM) reiterates FY 2025 GAAP EPS and Adjusted EPS guidance

Rhea-AI Filing Summary

Humana Inc. filed an update stating that senior management will meet with investors and analysts between September 1 and September 30, 2025, and intends to reaffirm its full-year 2025 guidance. The company continues to project approximately $13.77 in diluted earnings per common share (GAAP EPS) and approximately $17.00 in adjusted earnings per common share (Adjusted EPS) for the year ending December 31, 2025, consistent with guidance issued on July 30, 2025.

Humana explains that Adjusted EPS is a non-GAAP measure used alongside GAAP EPS to evaluate core operating performance and for planning and incentive compensation. For FY 2025, projected GAAP EPS of approximately $13.77 is adjusted by items such as $0.49 of amortization of identifiable intangibles, $3.01 of put/call valuation adjustments on certain minority interest investments, $0.44 related to value creation initiatives, $0.26 of impairment charges, and a cumulative net tax impact of $(0.97), resulting in projected Adjusted EPS of approximately $17.00. The company also notes it will not comment on 2026 Medicare Advantage Star Ratings until CMS releases final data in October.

0000049071false00000490712025-08-292025-08-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2025 (August 29, 2025)

Humana Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-5975			61-0647538
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

500 West Main Street, Louisville, Kentucky 40202

(Address of principal executive offices, including zip code)

(502) 580-1000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock			HUM			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 7.01. Regulation FD Disclosure.

Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between September 1, 2025 and September 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $13.77 in diluted earnings per common share (“EPS”) or approximately $17.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This guidance is consistent with the guidance issued in the Company’s press release dated July 30, 2025.

As indicated on the Company’s second quarter 2025 earnings call on July 30, 2025, the Company will not be commenting on 2026 Medicare Advantage (MA) Star Ratings (Bonus Year 2027) until the Centers for Medicare and Medicaid Services (CMS) releases final 2026 MA Star Ratings data in October.

The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles (“GAAP”). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company’s core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:

Diluted earnings per common share			FY 2025 Guidance
GAAP			Approximately  $13.77
Amortization of identifiable intangibles			0.49
Put/call valuation adjustments associated with the Company's non-consolidating minority interest investments (a)			3.01
Value creation initiatives (a)			0.44
Impairment charges (a)			0.26
Cumulative net tax impact			(0.97)
Adjusted (non-GAAP) – FY 2025 projected (a)			approximately $17.00

(a) FY 2025 GAAP EPS guidance and FY 2025 Adjusted (non-GAAP) EPS guidance exclude the impact of future value changes to items that are not yet probable or cannot be reasonably estimated at this time.

Cautionary Statement

This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, generally including the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions that are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the Company’s SEC filings.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMANA INC.
BY:			/s/ John-Paul W. Felter
			John-Paul W. Felter
			Senior Vice President, Chief Accounting Officer & Controller
			(Principal Accounting Officer)

Dated: August 29, 2025

FAQ

What earnings guidance did Humana (HUM) reaffirm for FY 2025?

Humana reaffirmed guidance for the year ending December 31, 2025 of approximately $13.77 in diluted earnings per common share (GAAP EPS) and approximately $17.00 in adjusted earnings per common share (Adjusted EPS).

How does Humana reconcile GAAP EPS to Adjusted EPS for FY 2025?

For FY 2025, Humana starts with GAAP EPS of approximately $13.77 and adjusts for $0.49 of amortization of identifiable intangibles, $3.01 of put/call valuation adjustments on non-consolidating minority interest investments, $0.44 from value creation initiatives, $0.26 of impairment charges, and a cumulative net tax impact of $(0.97), yielding projected Adjusted EPS of approximately $17.00.

Why does Humana use Adjusted EPS alongside GAAP EPS?

Humana states that Adjusted EPS, a non-GAAP measure, is used together with GAAP EPS to provide a more comprehensive view of its core operating performance over time. Management uses it as a consistent indicator of core business operations, for planning and decision-making, and in determining incentive compensation.

When will Humana discuss 2026 Medicare Advantage Star Ratings?

Humana notes that it will not comment on 2026 Medicare Advantage (MA) Star Ratings (Bonus Year 2027) until the Centers for Medicare and Medicaid Services releases final 2026 MA Star Ratings data in October.

What investor outreach is Humana conducting related to this guidance?

Members of Humana's senior management team are scheduled to meet with investors and analysts between September 1, 2025 and September 30, 2025, during which they intend to reaffirm the FY 2025 GAAP EPS and Adjusted EPS guidance.

Does Humana include any caution about its forward-looking EPS guidance?

Yes. Humana characterizes its EPS figures as forward-looking statements subject to risks, uncertainties, and assumptions, and refers readers to the Risk Factors section of its SEC filings for more information.